Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease entities : Galapagos nv save search
Chronic Kidney Disease Competitive Landscape Report 2023: Comprehensive Insights About 75+ Companies and 95+ Drugs
Published: 2023-05-05 (Crawled : 23:00) - prnewswire.com
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
| Email alert
Add to watchlist
GLPGF | News | $35.5157 71.75% 4.8K
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
| Email alert
Add to watchlist
disease companies report kidney
Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease
Published: 2023-02-08 (Crawled : 00:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.19%
H: 0.9%
C: -0.35%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -8.03%
H: 0.95%
C: 0.75%
disease topline trial results
Polycystic Kidney Disease Drugs Market Report by Technavio predicts USD 510.69 Mn growth -- Driven by the high prevalence of chronic kidney diseases
Published: 2022-09-09 (Crawled : 11:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 4.47%
H: 0.0%
C: 0.0%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 5.77%
H: 0.0%
C: -2.47%
XRTX | $3.5 -3.05% -3.14% 12K
|
Mining, Quarrying, and Oil and ...
|
| O: -0.72%
H: 1.46%
C: -3.65%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.59%
H: 0.27%
C: 0.06%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.11%
H: 0.0%
C: 0.0%
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 3.12%
H: 3.03%
C: 1.82%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 0.47%
H: 0.0%
C: -1.31%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.43%
H: 0.0%
C: -0.54%
disease report kidney growth market
Galapagos In-licenses Novel Drug Targets for Inflammatory Bowel Disease Discovered by Scipher Medicine’s Spectra™ Platform
Published: 2022-05-24 (Crawled : 15:00) - biospace.com/
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 0.76%
H: 0.16%
C: -0.75%
drug disease platform license
Inflammatory Bowel Disease Market Is Anticipated to Progress at a CAGR of 8.0% in the APAC Region for the Study Period of 2018 to 2030, Estimates DelveInsight
Published: 2022-04-11 (Crawled : 16:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 3.07%
H: 0.0%
C: -0.32%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 4.5%
H: 0.0%
C: 0.0%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -1.31%
H: 0.06%
C: -2.47%
disease market
Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
Published: 2021-11-22 (Crawled : 23:00) - biospace.com/
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -2.29%
H: 0.14%
C: -1.95%
glpg273 disease phase 2 trial kidney
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
Published: 2021-10-04 (Crawled : 06:00) - globenewswire.com
GLPGF | News | $35.5157 71.75% 4.8K
|
Health Technology
|
| O: -4.52%
H: 0.0%
C: 0.0%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -1.09%
H: 1.21%
C: -0.94%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -1.82%
H: 0.04%
C: -1.29%
disease phase 3 enroll
Crohn's Disease Market Set to Observe Remunerative Growth at a CAGR of 7.6% During the Study Period 2018-30
Published: 2021-07-29 (Crawled : 18:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.4%
H: 0.3%
C: -0.88%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 1.31%
H: 0.45%
C: -2.15%
disease growth
Global Kinase Inhibitors in Autoimmune Diseases Market to Continue on Growth Trajectory with 19.17% CAGR During the Study Period (2018-2030), Asserts DelveInsight
Published: 2021-04-19 (Crawled : 17:00) - prnewswire.com
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: -0.44%
H: 0.74%
C: 0.61%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.16%
H: 0.38%
C: 0.12%
EW | $85.94 -0.59% 0.0% 3.9M
|
Health Technology
|
| O: -0.73%
H: 0.75%
C: 0.22%
BSX | $67.33 -0.13% -0.31% 7M
|
Health Technology
|
| O: -0.29%
H: 0.44%
C: 0.22%
NUVA | $39.75 -2.24% -2.29% 0
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: -0.32%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.13%
H: 1.12%
C: -0.14%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 0.58%
H: 0.21%
C: -0.98%
disease growth
Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
Published: 2020-12-01 (Crawled : 21:02) - globenewswire.com
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -1.98%
H: 0.95%
C: 0.12%
disease trial phase 2 kidney
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.